{"id":"W1980672928","doi":"10.1016/j.cllc.2012.01.003","title":"Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; KRAS; Erlotinib Hydrochloride; Placebo; Lung cancer; Clinical endpoint; non-small cell lung cancer (NSCLC); Phases of clinical research; Epidermal growth factor receptor; Population; Clinical trial; Pharmacology; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001137206,0.0005093708,0.002261824,0.0002314117,0.00009884137,0.00002085676,0.0001681395,0.0001646978,0.0003738902],"category_scores_gemma":[0.0002813017,0.0003407226,0.0001887018,0.0005707858,0.0003231502,0.0002782445,0.00007420247,0.0003760347,0.000001568949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004729109,"about_ca_system_score_gemma":0.002174786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00123686,"about_ca_topic_score_gemma":0.001683124,"domain_scores_codex":[0.9957013,0.0004695381,0.001959335,0.0006916145,0.0005791004,0.0005991852],"domain_scores_gemma":[0.9950494,0.002354188,0.001097791,0.0004714809,0.0006141747,0.0004129842],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8745722,0.007682243,0.1029064,0.0005627602,0.002682317,0.00002325761,0.004685641,0.00386427,0.0000249321,0.000009721338,0.0003676422,0.00261864],"study_design_scores_gemma":[0.9717525,0.004508546,0.006709479,0.0009271642,0.008166714,0.000002389211,0.0009304098,0.006331748,0.0002162838,0.000001033208,0.00006574797,0.0003879703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9532639,0.003771293,0.001555062,0.00008819528,0.000484265,0.04032757,0.0001739848,0.00003841853,0.0002973086],"genre_scores_gemma":[0.9859086,0.0009790069,0.003020543,0.0001091237,0.0001392651,0.008151788,0.0001566995,0.00009167226,0.001443357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09718031,"threshold_uncertainty_score":0.9999045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06581369968642774,"score_gpt":0.4234511069001325,"score_spread":0.3576374072137048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}